Methylophiopogonanone A (MO-A; 10 μmol/L) significantly decreases apoptosis and cleaved caspase-3 expression, elevated the Bcl-2/Bax ratio and restored NO production. Pretreatment with Methylophiopogonanone A (MO-A) markedly increases the activation of PI3K/Akt/eNOS pathway in H9C2 cells subjected to H/R, and the protective effects of MO-A are abolished in the presence of the PI3K inhibitor wortmannin (100 nmol/L).
Methylophiopogonanone A (MO-A;10 mg/kg/d, po) for 2 weeks) protects cardiac function following myocardial I/R injury.